A reconciling interpretation is that intermediary molecules upstream along the amyloidogenic pathway, including the precursor APP and βCTF (β-C-terminal fragment), may be more relevant to AD phenotypes than Aβ itself. The gene discussed is APP; the disease is Alzheimer disease.